DX-2930 - 300mg/2wk
DX-2930-03
Phase 3 small_molecule completed
Quick answer
DX-2930 - 300mg/2wk for Hereditary Angioedema (HAE) is a Phase 3 program (small_molecule) at Takeda Pharmaceuticals International AG with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Takeda Pharmaceuticals International AG
- Indication
- Hereditary Angioedema (HAE)
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- completed